Local preparation for remitting pains and inflammation caused by nerpes virus

A topical preparation, herpes virus technology, applied in the field of diclofenac, can solve the problems of long recovery period, unattractive patients, high drug costs, etc.

Inactive Publication Date: 2004-09-22
YUNG SHIN PHARMACEUTICALS INDUSTRIAL CO LTD
View PDF7 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The relatively long recovery period required (i.e. patients typically take more than 2 weeks to recover) and high drug costs make these drugs unattractive for patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Local preparation for remitting pains and inflammation caused by nerpes virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Preparation of gels containing diclofenac

[0042] Element

Weight (g)

Diclofenac

10

L-menthol

10

Propylene Glycol

200

Triethanolamine

20

Carboxypolymethylene (Carbopol)

15

Isopropanol

250

pure water

375

total weight

880

[0043] The method for preparing the gel is as follows:

[0044] 1. Mix 15g Carbopol with 150g isopropanol. Then, add 375 g of purified water to the mixture, mix well to dissolve the carbopol and isopropanol in the purified water.

[0045] 2. Mix and dissolve 10g of diclofenac, 200g of propylene glycol and 50g of isopropanol.

[0046] 3. Add 10 g of L-menthol to 50 g of isopropanol and mix so that the L-menthol dissolves in the isopropanol.

[0047] 4. Add the mixture from steps 2 and 3 to the mixture from step 1 and mix until they are evenly distributed. Then, 20 g of triethanolamine was added to t...

Embodiment 2

[0049] Preparation of gels containing diclofenac

[0050] Element

Weight (g)

Diclofenac

296.15

L-menthol

200

Propylene Glycol

4000

Triethanolamine

400

Carboxypolymethylene (Carbopol)

200

Isopropanol

6900

pure water

7669.51

total weight

19665.66

[0051] Prepare topical formulations as follows:

[0052] 1. Mix 200g Carbopol with 150g isopropanol. Then, 7669.51 g of purified water was added to the mixture and mixed well to dissolve the carbopol and isopropanol in the purified water.

[0053] 2. Mix and dissolve 296.15g Diclofenac, 4000g Propylene Glycol and 50g Isopropanol.

[0054] 3. Add 200 g of L-menthol to 50 g of isopropanol and mix so that the L-menthol dissolves in the isopropanol.

[0055] 4. Add the mixture from steps 2 and 3 to the mixture from step 1 and mix until they are evenly distributed. Then, 400 g of triethanolami...

Embodiment 3

[0058] Solutions of the invention were prepared as follows:

[0059] 1. Add 29.615g of diclofenac to 4000g of ethanol, mix and dissolve.

[0060] 2. Add 2 g of L-menthol to the mixture from step 1 and mix until dissolved. Purified water is added and mixed with the mixture to a total volume of 8000 ml to obtain the topical formulation used in the present invention in the form of a solution.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A topical medicine for relaxing the pain and / or inflammation caused by herpes virus (HSV or VZV) contains diclofenac (or NSAID). The etodolac, ketoralac, ketoprofen, bromfenac, etc can be also contained. Its advantages are high curative effect and short course of treatment (7 days).

Description

technical field [0001] The present invention relates to a topical formulation comprising an NSAID, most preferably diclofenac. Other NSAIDs include, but are not limited to, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, thiopropene, methoxyphene meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, hydroxyphenylbutazone, and tolmidine. The topical formulation is particularly useful for the relief of pain / inflammation associated with infections caused by herpes viruses, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Background technique [0002] Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used drugs, probably due to their anti-inflammatory, analgesic, anti-pyretic and anti-thrombotic therapeutic properties, they are used to treat various manifestations such as pain, inflammation, febrile symptoms clinical disease, and for the treatment and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A61K9/00A61K9/10A61K9/70A61K31/19A61K31/195A61K31/196A61K31/381A61K31/40A61K31/405A61K31/407A61K31/415A61K31/54A61K47/00A61P29/00A61P31/22
CPCA61K31/19A61K31/54A61K31/381A61K31/405Y10S514/944A61K9/0014A61K31/196A61K31/195A61K31/415A61K31/40A61P17/00A61P29/00A61P31/22G06F3/1279
Inventor 李芳裕陈善炯陈炳崑蔡瓊如易延陵林威良
Owner YUNG SHIN PHARMACEUTICALS INDUSTRIAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap